Position in NVAX
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$139,350
New position
Shares Held
14,793
first reported quarter
Ownership
0.009%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#151
of 263 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Corient Private Wealth LLC holds $258,986,007 across 120 Biotechnology names. NVAX ranks #96 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
113,300 | $56,279,508 | |
| 2 | IONS |
Ionis Pharmaceuticals Inc
|
196,791 | $15,603,558 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
187,447 | $14,671,476 | |
| 4 | KRYS |
Krystal Biotech, Inc.
|
32,580 | $12,109,008 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
14,670 | $9,147,331 | |
| 6 | TECH |
BIO-TECHNE Corp
|
122,377 | $8,645,935 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
23,797 | $7,163,610 | |
| 8 | CLDX |
Celldex Therapeutics, Inc.
|
186,110 | $6,925,153 |
All Filings in NVAX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $139,350 | 14,793 | Shares | Defined | 2026-08-12 | |
| No filing history on record for this holder in this stock. | ||||||